鍙傝€冩枃鐚細<\/u><\/i><\/b><\/p> \n
[1].鏅撻┈.3000涓囩硸灏跨梾鎮h€咃紝瑕佸綋蹇�100澶氱骞跺彂鐥嘯J].涓€佸勾淇濆仴,2008(11):48.<\/p> \n
[2]. Mosenzon O, Alguwaihes A, Arenas Leon J.L., et al<\/i>. CAPTURE: a cross-sectional study of the contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes across 13 countries. Abstract 158. Presented at the 56th Annual Meeting of the European Association of the Study of Diabetes, Macrovascular complications and beyond, 10:15 CDT<\/span> on 24 September 2020<\/span>.<\/p> \n
[3]. Vencio S, Alguwaihes A, Arenas Leon J.L., et al<\/i>. Contemporary use of diabetes medications with a cardiovascular indication in adults with type 2 diabetes: a secondary analysis of the multinational CAPTURE study. Abstract 945. Presented at the 56th Annual Meeting of the European Association of the Study of Diabetes, Cardiovascular complications in humans through and through, 13:15 CDT<\/span> on 24 September 2020<\/span>.<\/p> \n
[4]. National Institute of Health (NIH). Atherosclerosis. Available at: https:\/\/www.nhlbi.nih.gov\/health-topics\/atherosclerosis<\/a> Last accessed: July 2020<\/span>.<\/p> \n
[7]. Cosentino F, Grant PJ, Aboyans V, et al<\/i>. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD), European Heart Journal. DOI: https:\/\/doi.org\/10.1093\/eurheartj\/ehz486<\/a>.<\/p> \n